Open Access Commentary

A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers"

Lisa H Butterfield*, Mary L Disis, Bernard A Fox, Peter P Lee, Samir N Khleif, Magdalena Thurin, Giorgio Trinchieri, Ena Wang, Jon Wigginton, Damien Chaussabel, George Coukos, Madhav Dhodapkar, Leif Håkansson, Sylvia Janetzki, Thomas O Kleen, John M Kirkwood, Cristina Maccalli, Holden Maecker, Michele Maio, Anatoli Malyguine, Giuseppe Masucci, A Karolina Palucka, Douglas M Potter, Antoni Ribas, Licia Rivoltini, Dolores Schendel, Barbara Seliger, Senthamil Selvan, Craig L Slingluff, David F Stroncek, Howard Streicher, Xifeng Wu, Benjamin Zeskind, Yingdong Zhao, Mai-Britt Zocca, Heinz Zwierzina and Francesco M Marincola*

Journal of Translational Medicine 2008, 6:81  doi:10.1186/1479-5876-6-81

PubMed Commons is an experimental system of commenting on PubMed abstracts, introduced in October 2013. Comments are displayed on the abstract page, but during the initial closed pilot, only registered users can read or post comments. Any researcher who is listed as an author of an article indexed by PubMed is entitled to participate in the pilot. If you would like to participate and need an invitation, please email, giving the PubMed ID of an article on which you are an author. For more information, see the PubMed Commons FAQ.

Additional information on the collaborative groups involved in the Taskforce

Lisa Butterfield   (2009-02-25 17:05)  University of Pittsburgh email

The iSBTc has brought together experts from multiple stakeholders who have been focusing significant effort in this area including the United States Food and Drug Administration (FDA); the National Cancer Institute (NCI); the National Institutes of Health (NIH); members from industry; and partnering organizations such as the Biotherapy Development Association (BDA), Association for Immunotherapy of Cancer (CIMT), Cancer Vaccine Consortium (CVC), Nordic Center for Development of Antitumour Vaccines (NCV-network), the Italian Network for Tumor Biotherapy (NIBIT) as well as academic experts in the field of immunologic biomarker development and standardization. The planned October 2009 workshop is unique in that it is meant to be an interactive exchange rather than merely a didactic exercise, as it is organized around lively discussion and sharing of data on biomarker development. Ultimately, the workshop will define the “state of the art” in assay and cellular product development and standardization.

"iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer", to take place October 28, 2009, Washington, D.C.

Competing interests

no competing interests, other than paper co-author and workshop co-organizer.


Post a comment